**Wednesday 22 Nov 2017**

### DIAEBOETY OPENING PLENARY SESSION

17:00-18:30 | Registrations
18:00-18:30 | OPENING OF MEETING

### STATE OF THE ART

#### STATE OF THE ART: BIG DATA IN DIAEBIOETY

- 08:40-09:00 | State of the Art - What have we learned from Big Data? - Obesity
- 09:00-09:30 | State of the Art - What have we learned from real world data on novel diabetes therapies?

### SESSION 1: THE BRAIN AS A TARGET FOR OBESITY THERAPY

- 09:30-10:00 | Functional neuroimaging in the development of novel anti-obesity interventions
- 10:00-10:30 | Can we smell obesity?
- 10:30-11:00 | Obesity, dysglycemia and cognitive decline: Evidence-based and current clinical practice for a bi-directional relationship

#### SESSION 2: NEW FRONTIERS IN DIABETES TREATMENT

- 11:00-11:30 | Gastroenterological tools for treating obesity and Post Bariatric Surgery complications
- 11:30-12:00 | Lifestyle strategies for relieving the Cardiometabolic impact of obesity via adipose tissues' redistribution subtyping?

### SESSION 3: ADIPOSE TISSUES IN OBESITY

- 12:00-12:30 | Can we reduce mortality in all patients with type 2 diabetes? Lessons from the new studies
- 12:30-13:00 | GLP-1 system expression & activation during acute & stable ischemic heart disease in patients with &without diabetes
- 13:00-13:30 | Obesity, dysglycemia and cognitive decline: Evidence-based and current clinical practice for a bi-directional relationship

#### SESSION 4: DIABETES IN SPECIAL POPULATIONS & SITUATIONS

- 13:30-14:00 | Assessing and managing Cardiometabolic risk at the workplace: making lifestyle habits vital signs

### SESSION 5: ANTI-OBESITY MEDICATION

- 14:00-14:30 | Can we prevent weight regain?
- 14:30-15:00 | Can all SGLT2 inhibitors be considered equal? From class effect to drug effect
- 15:00-15:30 | Impaired fasting glucose in children - what does it mean and should it be treated?

### SESSION 6: FOOD PREFERENCES & DIABESITY

- 15:30-16:00 | The new studies
- 16:00-16:30 | The new studies
- 16:30-17:00 | The new studies

### SESSION 7: GUT MICROBIOTA AND DIABESITY

- 07:30-07:50 | Gut microbiota manipulation in Obesity: promise and challenges
- 07:50-08:10 | Gut microbiota: The importance of diversity

#### SESSION 8: CHILDHOOD OBESITY

- 08:45-09:15 | Role of Gestational Diabetes in Metabolic Syndrome
- 09:15-09:45 | Should we use anticoagulants after bariatric surgery? - Review on the new balloon guidelines
- 09:45-10:15 | Can bariatric surgery reduce mortality?
- 10:15-10:45 | Hypoglycemia after bariatric surgery - how big is the problem?
- 10:45-11:15 | How can we predict Diabetes remission after Metabolic Surgery?

#### SESSION 9: BARIATRIC SURGERY AND DIABESITY

- 08:30-08:45 | CVG in diabetic and non-diabetic patients - Effect on glycemic control
- 08:45-09:00 | Role of cardiovascular risk factors and life style interventions in novel diabetes therapies
- 09:00-09:15 | How can molecular and functional signatures of adipose tissue guide clinical obesity treatment?
- 09:15-09:30 | Osteoporosis after gastric bypass surgery: is it preventable? A meta-analysis of prospective cohort studies
- 09:30-09:45 | Anti-obesity medication - Present and Future
- 09:45-10:15 | The role of ONG in Anti-obesity medication
- 10:15-10:45 | What is the place of Anti-obesity medication after bariatric surgery?
- 10:45-11:15 | Anti-obesity medication - Present and Future
- 11:15-11:30 | How can we prevent weight regain?
- 11:30-12:00 | SPRING SESSION SUMMARY: What should be the 1st line Metabolic/Bariatric Surgery?

### Weekend 22 Nov 2017

**Tuesday 21 Nov 2017**

**Wednesday 22 Nov 2017**

**Thursday 23 Nov 2017**

**Friday 24 Nov 2017**